Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis

Artificial Cells, Nanomedicine and Biotechnology

Volumn 43, Issue 1, 2015, Pages 33-39

  Agrawal, Udita ^a   Gupta, Madhu ^a   Vyas, S P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

CAP; Lipidic nanoparticle; Skin; Topical delivery

Indexed keywords

DERMATOLOGY; NANOPARTICLES; PARTICLE SIZE; SKIN; TARGETED DRUG DELIVERY;

AVERAGE PARTICLE SIZE; CUMULATIVE AMOUNT; EFFECTIVE THERAPY; ENTRAPMENT EFFICIENCY; NANOSTRUCTURED LIPID CARRIERS; SOLID LIPID NANOPARTICLES; SOLVENT DIFFUSION METHODS; TOPICAL DELIVERY;

CONTROLLED DRUG DELIVERY;

CAPSAICIN; DRUG CARRIER; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; SOLID LIPID NANOPARTICLE; UG FORMULATION; UNCLASSIFIED DRUG; ANTIPRURITIC AGENT; NANOPARTICLE; OLEIC ACID; PHOSPHATIDYLCHOLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG SOLUTION; EXPERIMENTAL SKIN IRRITATION; IN VITRO STUDY; IN VIVO STUDY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PATCH TEST; PSORIASIS; RAT; SKIN; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; RABBIT; SKIN ABSORPTION; TISSUE CULTURE TECHNIQUE; TRANSMISSION ELECTRON MICROSCOPY; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPRURITICS; BIOLOGICAL TRANSPORT; CAPSAICIN; DRUG CARRIERS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OLEIC ACID; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; PSORIASIS; RABBITS; RATS; SKIN; SKIN ABSORPTION; TISSUE CULTURE TECHNIQUES;

EID: 84920861775     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2013.832683     Document Type: Article

References (31)

1. Agarwal R, Katare OP, Vyas SP. 2001. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 228:43-52.
2. Agrawal U, Gupta M, Dube D, Vyas SP. 2012. Options and opportunities for clinical management and treatment of psoriasis. Crit Rev Ther Drug Carr Sys. 29:149-182.
3. Agrawal Y, Petkar KC, Sawant KK. 2010. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 401:93-102.
4. Almeida AJ, Souto E. 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 59:478-490.
5. Chhabra N, Aseri ML, Goyal V, Sankhla S. 2012. Capsaicin: a promising therapy - A critical reappraisal. Int J Nut Pharmacol Neurolog Dis. 2:8-15.
6. Das S, Ng WK, Tan RB. 2012. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 47:139-151.
7. Demerjian M, Mao MQ, Choi EH, Brown BE, Crumrine D, Chang S, et al. 2006. Topical treatment with thiazolidinediones, activators of peroxisome proliferators-activated receptor-c, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 15:154-160.
8. Desai PR, Marepally S, Patel AR, Voshavar C, Chaudhuri A, Singh M. 2013. Topical delivery of anti-TNFαsiRNA and capsaic-invianovel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release doi:10.1016/j.jconrel.2013.04.021.
9. El Maghraby GM, Barry BW, Williams AC. 2008. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 34:203-222.
10. Fang JY, Fang CL, Liu CH, Su YH. 2008. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 70:633-640.
11. Gupta M, Agrawal U, Vyas SP. 2012. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Exp Opin Drug Del 7:783-804.
12. Gupta M, Tiwari S, Vyas SP. 2011. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm Dev Technol. doi:10.3109/10837450.2011.598161.
13. Gupta M, Vyas SP. 2012. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phy Lip. 165:454-461.
14. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. 2005. Preparation and char-acterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces. 45:167-173.
15. Joshi M, Patravale V. 2008. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 346:124-132.
16. Knudsen N, Rønholt S, Salte RD, Jorgensen L, Thormann T, Basse LH, et al. 2012. Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm. 81:532-539.
17. Lin Y, Zih-Rou H, Rou-Zi Z, Fang J. 2010. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomed. 5:117-128.
18. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. 2007. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 328:191-195.
19. Lowes MA, Bowcock AM, Krueger JG. 2007. Pathogenesis and therapy of psoriasis. Nature. 445:866-873.
20. Magnusson BM, Koskinen LD. 2000. In vitro percutaneous penetration of topically applied capsaicin in relation to in vivo sensation responses. Int J Pharm. 195:55-62.
21. Pardeike J, Hommoss A, Muller RH. 2009. Lipid nanoparticles (SLN vs NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 366:170-184.
22. Qingzhi LV, Aihua Y, Yanwei X, Houli L, Zhimei S, Jing C, et al. 2009. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 372:191-198.
23. Raza K, Katare OP, Setia A, Bhatia A, Singh B. 2012. Improved therapeutic perform-ance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul. doi:10.3109/02652048.2012.717115.
24. Shah AK, Date AA, Joshi MD, Patraval VB. 2007. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 345:163-171.
25. Song Y, Kim C. 2006. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials. 27:271-280.
26. Souto EB, Wissing SA, Barbosa CM, Müller RH. 2004. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 278:71-77.
27. Teichmann A, Heuschkel S, Jacobi U, Presse G, Neubert RHH, Sterry W, Lademann J. 2007. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm. 66:159-164.
28. Vobalaboina V, Kopparam M. 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95:627-638.
29. Weyenberg W, Filev P, Van den Plas D, Vandervoort J, DeSmet K, Sollie P, Ludwig A. 2007. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm. 337:291-298.
30. Yu C. 2011. Study on HIF-1α gene translation in psoriatic epidermis with the topical treatment of capsaicin ointment. ISRN Pharm. 821874. doi:10.5402/2011/821874.
31. Zakir F, Vaidya B, Goyal AK, Malik B, Vyas SP. 2010. Development and char-acterization of oleic acid vesicles for the topical delivery of fluconazole. Drug Deliv. 17:238-248.